Programmed Cell Death-Ligand 1 Expression Status in Urothelial Carcinoma According to Clinical and Pathological Factors: A Multi-Institutional Retrospective Study
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q2Scopus Q3
- 저널
- FRONTIERS IN ONCOLOGY10 · 2020
- 피인용
- Web of Science 4Scopus 5
- FWCI (Scopus)
- 0
- JCR IF
- JCR 2019 4.848
- ISSN
- 2234-943X
저자
- Kim, Hyung Suk제1저자Department of Urology, Dongguk University Ilsan Medical Center, Dongguk University College of Medicine, Goyang, South Korea
- Jang, Won SikDepartment of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, South Korea
- Ham, Won SikDepartment of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, South Korea
- Jung, Seung IlDepartment of Urology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasum, South Korea
- Lee, Dong HyunDepartment of Urology, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, South Korea
- Ku, Ja HyeonDepartment of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea
- 하홍구Department of Urology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, South Korea
- 구자윤Department of Urology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, South Korea
- Choi, Se YoungDepartment of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, South Korea
- Chang, In HoDepartment of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, South Korea
- Choi, TaesooDepartment of Urology, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea
- Song, WanDepartment of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
- Jeon, Seong SooDepartment of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
- Jeong, Byong ChangDepartment of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
- Kim, Sung HanDepartment of Urology, Center for Urologic Cancer, Hospital and Division of Tumor Immunology, Research Institute, National Cancer Center, Goyang, South Korea
- Seo, Ho Kyung교신저자Department of Urology, Center for Urologic Cancer, Hospital and Division of Tumor Immunology, Research Institute, National Cancer Center, Goyang, South Korea
초록
Purpose:To investigate programmed cell death-ligand 1 (PD-L1) expression status and the clinical and pathological factors related to its expression in urothelial carcinoma (UC) patients. Materials and Methods:Data from 761 UC patients who underwent testing for PD-L1 expression using the VENTANA (SP-142 immunohistochemistry assay) for measuring PD-L1 expression according to the manufacturer's protocol between February 2016 and July 2019 were retrospectively reviewed. Patients were categorized into three groups based on the percentage of tumor area covered by PD-L1-expressing tumor-infiltrating immune cells (ICs) as follows: IC0 (<1%), IC1 (>= 1% and <5%), and IC2/3 (>= 5%). Positive PD-L1 expression was defined as IC2/3 (>= 5%). The factors related to positive PD-L1 expression were assessed by using unadjusted and adjusted logistic regression analyses. Results:In the entire cohort, 213 (28%) patients showed positive PD-L1 expression. Final adjusted regression analyses for positive PD-L1 expression revealed that several factors, including intravesical BCG prior to PD-L1 testing (odds ratio [OR] 0.57, 95% confidence interval [CI] 0.37-0.96), advanced tumor stage (stage III/IV) (OR 2.04, 95% CI 1.41-2.93), and high tumor grade (OR 5.31, 95% CI 2.38-11.83) were significantly associated with positive PD-L1 expression. Conclusions:This study showed that the PD-L1 expression is associated with several clinical and pathological factors for the first time in a real-world setting. Further follow-up clinical trials should consider adjusting these factors, including intravesical BCG treatment, tumor stage and grade to clarify the utility of PD-L1 as a biomarker.
키워드
urothelial carcinomaimmune cellprogrammed cell death-ligand 1immunohistochemistryimmune checkpointCISPLATIN-INELIGIBLE PATIENTSSINGLE-ARMPD-L1 EXPRESSIONBLADDER-CANCERMULTICENTERPEMBROLIZUMABATEZOLIZUMABSURVIVALBLOCKADETHERAPY
식별자
- Scopus EID
- 2-s2.0-85092764146
- WoS UID
- 000578277300001



로그인
연구물 목록으로